FigureS4 from Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer

FigureS4 from Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer

<p>FigureS4</p>

Kaydedildi:

Detaylı Bibliyografya
Yazar:	Jonathan Chou (14957015) (author)
Diğer Yazarlar:	Emily A. Egusa (14962343) (author), Sinan Wang (14962346) (author), Michelle L. Badura (14962349) (author), Fei Lee (14962352) (author), Anil P. Bidkar (14962355) (author), Jun Zhu (14962358) (author), Tanushree Shenoy (14957003) (author), Kai Trepka (14962361) (author), Troy M. Robinson (14962364) (author), Veronica Steri (14962367) (author), Jiaoti Huang (14962370) (author), Yuzhuo Wang (14962373) (author), Eric J. Small (14962376) (author), Emily Chan (14962379) (author), Bradley A. Stohr (14962382) (author), Alan Ashworth (14957030) (author), Brant Delafontaine (14962385) (author), Sylvie Rottey (14962388) (author), Keegan S. Cooke (14962391) (author), Nooshin Hashemi Sadraei (14962394) (author), Brian Yu (14962397) (author), Mark Salvati (14962400) (author), Julie M. Bailis (14962403) (author), Felix Y. Feng (14845891) (author), Robert R. Flavell (9563200) (author), Rahul Aggarwal (14960826) (author)
Baskı/Yayın Bilgisi:	2025
Konular:	Cancer Therapeutic Research and Development Immuno-oncology Methods and Technology Drug Targets Cell surface receptor drug targets Genitourinary Cancers Prostate cancer Imaging Positron emission tomography (PET) Immunotherapy Preclinical Models Xenograft models
Etiketler:	Etiketle Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller

FigureS1 from Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer
Yazar:: Jonathan Chou (14957015)
Baskı/Yayın Bilgisi: (2025)

FigureS10 from Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer
Yazar:: Jonathan Chou (14957015)
Baskı/Yayın Bilgisi: (2025)

FigureS2 from Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer
Yazar:: Jonathan Chou (14957015)
Baskı/Yayın Bilgisi: (2025)

FigureS3 from Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer
Yazar:: Jonathan Chou (14957015)
Baskı/Yayın Bilgisi: (2025)

FigureS5 from Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer
Yazar:: Jonathan Chou (14957015)
Baskı/Yayın Bilgisi: (2025)

FigureS6 from Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer
Yazar:: Jonathan Chou (14957015)
Baskı/Yayın Bilgisi: (2025)

FigureS7 from Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer
Yazar:: Jonathan Chou (14957015)
Baskı/Yayın Bilgisi: (2025)

FigureS8 from Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer
Yazar:: Jonathan Chou (14957015)
Baskı/Yayın Bilgisi: (2025)

FigureS9 from Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer
Yazar:: Jonathan Chou (14957015)
Baskı/Yayın Bilgisi: (2025)

Supplementary MovieS 1a from Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer
Yazar:: Jonathan Chou (14957015)
Baskı/Yayın Bilgisi: (2025)

Supplementary MovieS1b from Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer
Yazar:: Jonathan Chou (14957015)
Baskı/Yayın Bilgisi: (2025)

Supplementary MovieS1c from Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer
Yazar:: Jonathan Chou (14957015)
Baskı/Yayın Bilgisi: (2025)

Supplementary MovieS1d from Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer
Yazar:: Jonathan Chou (14957015)
Baskı/Yayın Bilgisi: (2025)

Supplementary MovieS2a from Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer
Yazar:: Jonathan Chou (14957015)
Baskı/Yayın Bilgisi: (2025)

Supplementary MovieS2b from Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer
Yazar:: Jonathan Chou (14957015)
Baskı/Yayın Bilgisi: (2025)

Supplementary MovieS2c from Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer
Yazar:: Jonathan Chou (14957015)
Baskı/Yayın Bilgisi: (2025)

Supplementary Video S1 from First-in-Human Study of the Radioligand <sup>68</sup>Ga-N188 Targeting Nectin-4 for PET/CT Imaging of Advanced Urothelial Carcinoma
Yazar:: Xiaojiang Duan (15439264)
Baskı/Yayın Bilgisi: (2025)

Supplementary Video S2A from First-in-Human Study of the Radioligand <sup>68</sup>Ga-N188 Targeting Nectin-4 for PET/CT Imaging of Advanced Urothelial Carcinoma
Yazar:: Xiaojiang Duan (15439264)
Baskı/Yayın Bilgisi: (2025)

Supplementary Video S2B from First-in-Human Study of the Radioligand <sup>68</sup>Ga-N188 Targeting Nectin-4 for PET/CT Imaging of Advanced Urothelial Carcinoma
Yazar:: Xiaojiang Duan (15439264)
Baskı/Yayın Bilgisi: (2025)

Supplementary Video S2C from First-in-Human Study of the Radioligand <sup>68</sup>Ga-N188 Targeting Nectin-4 for PET/CT Imaging of Advanced Urothelial Carcinoma
Yazar:: Xiaojiang Duan (15439264)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table 2 from Targeting CD44 Variant 5 with an Antibody–Drug Conjugate Is an Effective Therapeutic Strategy for Intrahepatic Cholangiocarcinoma
Yazar:: Yuncheng Bei (16546095)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table S1 from Targeting CD44 Variant 5 with an Antibody–Drug Conjugate Is an Effective Therapeutic Strategy for Intrahepatic Cholangiocarcinoma
Yazar:: Yuncheng Bei (16546095)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table S3 from Targeting CD44 Variant 5 with an Antibody–Drug Conjugate Is an Effective Therapeutic Strategy for Intrahepatic Cholangiocarcinoma
Yazar:: Yuncheng Bei (16546095)
Baskı/Yayın Bilgisi: (2025)

Table S1 from Proteomic Profiling of Extracellular Matrix Components from Patient Metastases Identifies Consistently Elevated Proteins for Developing Nanobodies That Target Primary Tumors and Metastases
Yazar:: Noor Jailkhani (16015810)
Baskı/Yayın Bilgisi: (2025)

Table S2 from Proteomic Profiling of Extracellular Matrix Components from Patient Metastases Identifies Consistently Elevated Proteins for Developing Nanobodies That Target Primary Tumors and Metastases
Yazar:: Noor Jailkhani (16015810)
Baskı/Yayın Bilgisi: (2025)

Table S3 from Proteomic Profiling of Extracellular Matrix Components from Patient Metastases Identifies Consistently Elevated Proteins for Developing Nanobodies That Target Primary Tumors and Metastases
Yazar:: Noor Jailkhani (16015810)
Baskı/Yayın Bilgisi: (2025)

Supplemental Data File S3 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
Yazar:: Katie E. Hebron (15046889)
Baskı/Yayın Bilgisi: (2025)

Supplementary Data File S1 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
Yazar:: Katie E. Hebron (15046889)
Baskı/Yayın Bilgisi: (2025)

Supplementary Data File S2 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
Yazar:: Katie E. Hebron (15046889)
Baskı/Yayın Bilgisi: (2025)

Supplementary Data File S6 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
Yazar:: Katie E. Hebron (15046889)
Baskı/Yayın Bilgisi: (2025)

Supplementary Data File S7 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
Yazar:: Katie E. Hebron (15046889)
Baskı/Yayın Bilgisi: (2025)

Supplementary Data File S8 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
Yazar:: Katie E. Hebron (15046889)
Baskı/Yayın Bilgisi: (2025)

Supplementary Data File S9 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
Yazar:: Katie E. Hebron (15046889)
Baskı/Yayın Bilgisi: (2025)

Supplementary Data S1 from Determinants of Survival with Combined HER2 and PD-1 Blockade in Metastatic Esophagogastric Cancer
Yazar:: Steven B. Maron (15044607)
Baskı/Yayın Bilgisi: (2025)

Supplementary Figure 1 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
Yazar:: Anne-Florence Blandin (15056366)
Baskı/Yayın Bilgisi: (2025)

Supplementary Figure 2 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
Yazar:: Anne-Florence Blandin (15056366)
Baskı/Yayın Bilgisi: (2025)

Supplementary Figure 3 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
Yazar:: Anne-Florence Blandin (15056366)
Baskı/Yayın Bilgisi: (2025)

Supplementary Figure 4 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
Yazar:: Anne-Florence Blandin (15056366)
Baskı/Yayın Bilgisi: (2025)

Supplementary Figure 5 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
Yazar:: Anne-Florence Blandin (15056366)
Baskı/Yayın Bilgisi: (2025)

Supplementary Figure 6 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
Yazar:: Anne-Florence Blandin (15056366)
Baskı/Yayın Bilgisi: (2025)

Cannot write session to /tmp/vufind_sessions/sess_b7grjrl1asfjsh9rmv8h4e0sjh